{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T20:07:22Z","timestamp":1789762042842,"version":"4.0.1"},"reference-count":57,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.urolonc.2026.06.022","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T11:37:20Z","timestamp":1784288240000},"page":"664-670","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Emerging antibody-drug conjugates in metastatic castration-resistant prostate cancer"],"prefix":"10.1016","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1898-5501","authenticated-orcid":false,"given":"Charles B.","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachery R.","family":"Reichert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.urolonc.2026.06.022_bib0001","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \"biological missile\" for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.urolonc.2026.06.022_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104979","article-title":"Bystander effect in antibody-drug conjugates: navigating the fine line in tumor heterogeneity","volume":"216","author":"Wang","year":"2025","journal-title":"Crit Rev Oncol Hematol"},{"issue":"4","key":"10.1016\/j.urolonc.2026.06.022_bib0003","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1158\/1078-0432.CCR-25-3103","article-title":"Predictive biomarkers of antibody-drug conjugate efficacy for solid tumors: current challenges and the potential role of quantitative proteomics","volume":"32","author":"McNamee","year":"2026","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.urolonc.2026.06.022_bib0004","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.1016\/j.apsb.2023.06.015","article-title":"Antibody-drug conjugates: recent advances in payloads","volume":"13","author":"Wang","year":"2023","journal-title":"Acta Pharm Sin B"},{"issue":"1","key":"10.1016\/j.urolonc.2026.06.022_bib0005","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13045-025-01704-3","article-title":"Antibody-drug conjugates (ADCs): current and future biopharmaceuticals","volume":"18","author":"Wang","year":"2025","journal-title":"J Hematol Oncol"},{"issue":"12","key":"10.1016\/j.urolonc.2026.06.022_bib0006","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1038\/bjc.2017.367","article-title":"Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required?","volume":"117","author":"Staudacher","year":"2017","journal-title":"Br J Cancer"},{"issue":"10","key":"10.1016\/j.urolonc.2026.06.022_bib0007","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.urolonc.2026.06.022_bib0008","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.2217\/fon-2021-0273","article-title":"Perioperative pembrolizumab therapy in muscle-invasive bladder cancer: phase III KEYNOTE-866 and KEYNOTE-905\/EV-303","volume":"17","author":"Galsky","year":"2021","journal-title":"Fut Oncol"},{"issue":"2","key":"10.1016\/j.urolonc.2026.06.022_bib0009","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/S0090-4295(96)00184-7","article-title":"Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy","volume":"48","author":"Wright","year":"1996","journal-title":"Urology"},{"issue":"5","key":"10.1016\/j.urolonc.2026.06.022_bib0010","doi-asserted-by":"crossref","first-page":"596","DOI":"10.2967\/jnumed.120.257238","article-title":"Current and emerging clinical applications of PSMA PET diagnostic imaging for prostate cancer","volume":"62","author":"Farolfi","year":"2021","journal-title":"J Nucl Med"},{"issue":"12","key":"10.1016\/j.urolonc.2026.06.022_bib0011","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.urolonc.2026.06.022_bib0012","doi-asserted-by":"crossref","first-page":"530.e15","DOI":"10.1016\/j.urolonc.2016.07.005","article-title":"Phase 1\/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer","volume":"34","author":"Milowsky","year":"2016","journal-title":"Urol Oncol"},{"issue":"6_suppl","key":"10.1016\/j.urolonc.2026.06.022_bib0013","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1200\/jco.2013.31.6_suppl.119","article-title":"Prostate-specific membrane antigen antibody drug conjugate (PSMA ADC): a phase I trial in metastatic castration-resistant prostate cancer (mCRPC) previously treated with a taxane","volume":"31","author":"Petrylak","year":"2013","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.urolonc.2026.06.022_bib0014","doi-asserted-by":"crossref","first-page":"3602","DOI":"10.1158\/1078-0432.CCR-20-4528","article-title":"Phase I study of MEDI3726: a prostate-specific membrane antigen-targeted antibody-drug conjugate, in patients with mCRPC after failure of abiraterone or enzalutamide","volume":"27","author":"de Bono","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2026.06.022_bib0015","doi-asserted-by":"crossref","first-page":"S974","DOI":"10.1016\/j.annonc.2023.09.2752","article-title":"APEX-01: first-in-human phase I\/II study of ARX517 an anti- prostate-specific membrane antigen (PSMA) antibody-drug conjugate (ADC) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)","volume":"34","author":"Shen","year":"2023","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.urolonc.2026.06.022_bib0016","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.eururo.2022.09.004","article-title":"B7-H3 as a therapeutic target in advanced prostate cancer","volume":"83","author":"Guo","year":"2023","journal-title":"Eur Urol"},{"issue":"9","key":"10.1016\/j.urolonc.2026.06.022_bib0017","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/ni967","article-title":"The B7 family member B7-H3 preferentially down-regulates T helper type 1-mediated immune responses","volume":"4","author":"Suh","year":"2003","journal-title":"Nat Immunol"},{"issue":"49","key":"10.1016\/j.urolonc.2026.06.022_bib0018","doi-asserted-by":"crossref","first-page":"19458","DOI":"10.1073\/pnas.0709802104","article-title":"B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome","volume":"104","author":"Zang","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.urolonc.2026.06.022_bib0019","doi-asserted-by":"crossref","first-page":"S996","DOI":"10.1016\/j.annonc.2024.08.1735","article-title":"AMARACK: randomized Phase II trial of the B7-H3 targeting antibody drug conjugate (ADC) vobramitamab duocarmazine (vobra duo) in metastatic castration-resistant prostate cancer (mCRPC)","volume":"35","author":"de Bono","year":"2024","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.urolonc.2026.06.022_bib0020","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1038\/s41591-025-03600-2","article-title":"A B7H3-targeting antibody-drug conjugate in advanced solid tumors: a phase 1\/1b trial","volume":"31","author":"Ma","year":"2025","journal-title":"Nat Med"},{"issue":"16_suppl","key":"10.1016\/j.urolonc.2026.06.022_bib0021","doi-asserted-by":"crossref","first-page":"5015","DOI":"10.1200\/JCO.2025.43.16_suppl.5015","article-title":"DB-1311\/BNT324 (a novel B7H3 ADC) in patients with heavily pretreated castrate-resistant prostate cancer (CRPC)","volume":"43","author":"Parsonson","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.06.022_bib0022","doi-asserted-by":"crossref","first-page":"S481","DOI":"10.1016\/j.annonc.2023.09.1876","article-title":"Ifinatamab deruxtecan (I-DXd; DS-7300) in patients with advanced solid tumors: updated clinical and biomarker results from a phase I\/II study","volume":"34","author":"Patel","year":"2023","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.urolonc.2026.06.022_bib0023","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1200\/JCO-25-02142","article-title":"Ifinatamab deruxtecan in patients with extensive-stage small cell lung cancer: primary analysis of the phase II IDeate-Lung01 trial","volume":"44","author":"Rudin","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.06.022_bib0024","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.2147\/DDDT.S508773","article-title":"A systematic review of mechanisms, incidence, and management of trastuzumab deruxtecan induced ILD\/pneumonitis in solid tumors","volume":"19","author":"Liao","year":"2025","journal-title":"Drug Des Devel Ther"},{"issue":"2","key":"10.1016\/j.urolonc.2026.06.022_bib0025","doi-asserted-by":"crossref","first-page":"833","DOI":"10.21037\/tcr-23-1537","article-title":"B7-H3 promotes proliferation and migration of lung cancer cells by modulating PI3K\/AKT pathway via ENO1 activity","volume":"13","author":"Wu","year":"2024","journal-title":"Transl Cancer Res"},{"issue":"17","key":"10.1016\/j.urolonc.2026.06.022_bib0026","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1016\/j.yexcr.2013.07.025","article-title":"Six-transmembrane epithelial antigen of the prostate-1 plays a role for in vivo tumor growth via intercellular communication","volume":"319","author":"Yamamoto","year":"2013","journal-title":"Exp Cell Res"},{"issue":"22","key":"10.1016\/j.urolonc.2026.06.022_bib0027","doi-asserted-by":"crossref","DOI":"10.1172\/JCI169655","article-title":"Antitumor activity of AZD0754, a dnTGFbetaRII-armored, STEAP2-targeted CAR-T cell therapy, in prostate cancer","volume":"133","author":"Zanvit","year":"2023","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.urolonc.2026.06.022_bib0028","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1158\/2159-8290.CD-23-0964","article-title":"Xaluritamig, a STEAP1 x CD3 XmAb 2+1 immune therapy for metastatic castration-resistant prostate cancer: results from dose exploration in a first-in-human study","volume":"14","author":"Kelly","year":"2024","journal-title":"Cancer Discov"},{"issue":"8_supplement_1","key":"10.1016\/j.urolonc.2026.06.022_bib0029","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1158\/1538-7445.AM2025-1159","article-title":"Preclinical characterization of a novel STEAP1 antibody-drug conjugate ADRX-0405 for the treatment of mCRPC","volume":"85","author":"Shahmoradgoli","year":"2025","journal-title":"Cancer Res"},{"issue":"16_suppl","key":"10.1016\/j.urolonc.2026.06.022_bib0030","doi-asserted-by":"crossref","first-page":"5014","DOI":"10.1200\/JCO.2026.44.16_suppl.5014","article-title":"A phase 1, first-in-human (FIH) study evaluating the safety, pharmacokinetics, and efficacy of ABBV-969 in patients with metastatic castration-resistant prostate cancer (mCRPC)","volume":"44","author":"Dorff","year":"2026","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2026.06.022_bib0031","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/s41598-023-50215-z","article-title":"High expression of Trop2 is associated with aggressive localized prostate cancer and is a candidate urinary biomarker","volume":"14","author":"Liu","year":"2024","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.urolonc.2026.06.022_bib0032","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1073\/pnas.1905384117","article-title":"Trop2 is a driver of metastatic prostate cancer with neuroendocrine phenotype via PARP1","volume":"117","author":"Hsu","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"issue":"12","key":"10.1016\/j.urolonc.2026.06.022_bib0033","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1158\/1078-0432.CCR-22-1305","article-title":"Expression and therapeutic targeting of TROP-2 in treatment-resistant prostate cancer","volume":"29","author":"Sperger","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.urolonc.2026.06.022_bib0034","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41698-024-00599-6","article-title":"Assessment of TROP2, CEACAM5 and DLL3 in metastatic prostate cancer: expression landscape and molecular correlates","volume":"8","author":"Ajkunic","year":"2024","journal-title":"NPJ Precis Oncol"},{"issue":"16","key":"10.1016\/j.urolonc.2026.06.022_bib0035","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab Govitecan in metastatic triple-negative breast cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.urolonc.2026.06.022_bib0036","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.annonc.2024.01.002","article-title":"TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomes","volume":"35","author":"Loriot","year":"2024","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.urolonc.2026.06.022_bib0037","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.annonc.2025.01.011","article-title":"Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial","volume":"36","author":"Powles","year":"2025","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.urolonc.2026.06.022_bib0038","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.7320","article-title":"Preclinical evidence for the use of anti-Trop-2 antibody-drug conjugate Sacituzumab govitecan in cerebral metastasized castration-resistant prostate cancer","volume":"13","author":"Weiten","year":"2024","journal-title":"Cancer Med"},{"key":"10.1016\/j.urolonc.2026.06.022_bib0039","doi-asserted-by":"crossref","first-page":"S993","DOI":"10.1016\/j.annonc.2024.08.1729","article-title":"Final clinical and liquid biopsy (LBx) results of phase II trial of sacituzumab govitecan (SG) in patients (Pts) with metastatic castration resistant prostate cancer (mCRPC) progressing on androgen receptor signaling inhibitors (ARSI)","volume":"35","author":"Lang","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urolonc.2026.06.022_bib0040","article-title":"Sacituzumab tirumotecan (sac-TMT) + pembrolizumab (Pembro) in metastatic castration-resistant pro","volume":"36","author":"Bian","year":"2025","journal-title":"Ann Oncol"},{"issue":"24","key":"10.1016\/j.urolonc.2026.06.022_bib0041","doi-asserted-by":"crossref","first-page":"6207","DOI":"10.1158\/0008-5472.CAN-21-3360","article-title":"HER3 Is an actionable target in advanced prostate cancer","volume":"81","author":"Gil","year":"2021","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.urolonc.2026.06.022_bib0042","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1186\/s12967-024-05133-7","article-title":"DB-1310, an ADC comprised of a novel anti-HER3 antibody conjugated to a DNA topoisomerase I inhibitor, is highly effective for the treatment of HER3-positive solid tumors","volume":"22","author":"Li","year":"2024","journal-title":"J Transl Med"},{"issue":"17","key":"10.1016\/j.urolonc.2026.06.022_bib0043","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.121497","article-title":"Targeting CD46 for both adenocarcinoma and neuroendocrine prostate cancer","volume":"3","author":"Su","year":"2018","journal-title":"JCI Insight"},{"issue":"15","key":"10.1016\/j.urolonc.2026.06.022_bib0044","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1200\/JCO-24-01989","article-title":"Phase I, first-in-Human study of FOR46 (FG-3246), an immune-modulating antibody-drug conjugate targeting CD46, in patients with metastatic castration-resistant prostate cancer","volume":"43","author":"Aggarwal","year":"2025","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.urolonc.2026.06.022_bib0045","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1002\/pros.24846","article-title":"Nectin-4 expression in prostatic adenocarcinoma: an immunohistochemical study","volume":"85","author":"Baraban","year":"2025","journal-title":"Prostate"},{"issue":"14","key":"10.1016\/j.urolonc.2026.06.022_bib0046","doi-asserted-by":"crossref","DOI":"10.1111\/jcmm.18572","article-title":"Exploring membranous NECTIN-4 expression patterns and enfortumab vedotin response in prostate cancer","volume":"28","author":"Weiten","year":"2024","journal-title":"J Cell Mol Med"},{"issue":"4_suppl","key":"10.1016\/j.urolonc.2026.06.022_bib0047","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1200\/JCO.2024.42.4_suppl.152","article-title":"Enfortumab vedotin (EV) as monotherapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): results of stage I of a phase 2 trial","volume":"42","author":"Swami","year":"2024","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2026.06.022_bib0048","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01.pai.0000213157.94804.fc","article-title":"Expression of tissue factor in prostate cancer correlates with malignant phenotype","volume":"16","author":"Kaushal","year":"2008","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"6","key":"10.1016\/j.urolonc.2026.06.022_bib0049","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/S0090-4295(03)00768-4","article-title":"Tissue factor expression and prognosis in patients with metastatic prostate cancer","volume":"62","author":"Akashi","year":"2003","journal-title":"Urology"},{"issue":"18","key":"10.1016\/j.urolonc.2026.06.022_bib0050","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1007\/s40265-021-01633-8","article-title":"Tisotumab vedotin: first approval","volume":"81","author":"Markham","year":"2021","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.urolonc.2026.06.022_bib0051","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S1470-2045(18)30859-3","article-title":"Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial","volume":"20","author":"de Bono","year":"2019","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2026.06.022_bib0052","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/s41698-025-01131-0","article-title":"The evolving landscape of antibody-drug conjugates (ADCs) for treatment of prostate cancer","volume":"9","author":"Lin","year":"2025","journal-title":"NPJ Precis Oncol"},{"issue":"23","key":"10.1016\/j.urolonc.2026.06.022_bib0053","doi-asserted-by":"crossref","first-page":"6916","DOI":"10.1158\/1078-0432.CCR-19-1423","article-title":"The role of lineage plasticity in prostate cancer therapy resistance","volume":"25","author":"Beltran","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"18","key":"10.1016\/j.urolonc.2026.06.022_bib0054","doi-asserted-by":"crossref","first-page":"3854","DOI":"10.1158\/1078-0432.CCR-25-1211","article-title":"Safety and efficacy of tarlatamab in patients with neuroendocrine prostate cancer: results from the phase 1b DeLLpro-300 study","volume":"31","author":"Aggarwal","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.urolonc.2026.06.022_bib0055","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41698-021-00214-y","article-title":"A phase I\/II study of rovalpituzumab tesirine in delta-like 3-expressing advanced solid tumors","volume":"5","author":"Mansfield","year":"2021","journal-title":"NPJ Precis Oncol"},{"issue":"9","key":"10.1016\/j.urolonc.2026.06.022_bib0056","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/j.jtho.2021.07.012","article-title":"All that glitters is not gold: the story of rovalpituzumab tesirine in SCLC","volume":"16","author":"Uprety","year":"2021","journal-title":"J Thorac Oncol"},{"issue":"3","key":"10.1016\/j.urolonc.2026.06.022_bib0057","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1158\/1078-0432.CCR-20-3396","article-title":"Regulation of CEACAM5 and therapeutic efficacy of an anti-CEACAM5-SN38 antibody-drug conjugate in neuroendocrine prostate cancer","volume":"27","author":"DeLucia","year":"2021","journal-title":"Clin Cancer Res"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926005806?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926005806?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T19:20:31Z","timestamp":1789759231000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143926005806"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":57,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S1078143926005806"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.06.022","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging antibody-drug conjugates in metastatic castration-resistant prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.06.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}